TALIS BIOMEDICAL CORP (TLIS) Stock Institutional Trading Activity


TALIS BIOMEDICAL CORP (TLIS) position changes reported by tracked institutional filers across multiple SEC 13F reporting periods. Based on recent SEC 13F filings (Q2 2024), investors with some of the largest reported share count changes include Renaissance Technologies LLC and Greenlight Capital. Explore insights into buying and selling patterns, position changes, and investment conviction levels to understand institutional trading behavior and market dynamics.

Explore more:

Portfolio quarterNameTypeQuantityRemainingReported stock balance
Q2 2024Renaissance Technologies LLCBuy2,00012,299$106,531
Q1 2024Renaissance Technologies LLCBuy10,29910,299$90
Q3 2023Greenlight CapitalBuy149,052149,052$860,030

Frequently asked questions about TLIS activity

  • Which institutional owners are buying TLIS?

    Institutional owners buying TLIS include investors who have either initiated new positions or increased their existing holdings based on recent SEC 13F filings. The activity table above highlights which funds added shares in the latest reporting periods and how their positions changed over time.

  • What does "buy" mean in TLIS activity?

    "Buy" means an investor increased their reported position in TLIS compared to the prior reporting period. This reflects growing exposure to TALIS BIOMEDICAL CORP (TLIS) rather than necessarily a brand-new position (though new positions also appear as buys when prior quantity was zero).

  • Is institutional interest in TLIS increasing?

    Institutional interest in TLIS can be assessed by comparing the number of tracked funds adding or increasing positions versus those trimming or exiting across the periods shown. A higher number of additions typically signals increasing participation among large filers, but it should be read alongside position sizes and the full table.